Home › Funds › Prosight Management, LP › BBIO
Prosight Management, LP position in BBIO
BRIDGEBIO PHARMA INC · Health Care
Prosight Management, LP reported holding 150,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$9.9M, representing 1.91% of its reported portfolio and ranking #18 among its reported holdings. Prosight Management, LP has disclosed BBIO holdings in 9 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Prosight Management, LP's BBIO position evolved
Prosight Management, LP first disclosed a stake in BBIO in Q1 2024 at 589,530 shares (US$18.2M). The position peaked in Q3 2024 at 1,086,810 shares, worth US$27.7M. Across 9 filings, Prosight Management, LP increased the stake 2 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 150,000 shares valued at US$9.9M. Notable position changes include a 39% trim in Q1 2025 (shares rose 25% over the following quarter), a 44% trim in Q3 2025 (shares rose 47% over the following quarter), a 89% trim in Q4 2025 (shares fell 3% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 589.53K | $18.23M | New |
| Q2 2024 | 800.00K | $20.26M | Add |
| Q3 2024 | 1.09M | $27.67M | Add |
| Q4 2024 | 995.00K | $27.30M | Reduce |
| Q1 2025 | 610.00K | $21.09M | Reduce |
| Q2 2025 | 472.69K | $20.41M | Reduce |
| Q3 2025 | 264.50K | $13.74M | Reduce |
| Q4 2025 | 30.00K | $2.29M | Reduce |
| Q3 2026 | 150.00K | $9.87M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBIO and 13F data
BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 39 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBIO
- Jupiter Topco LLC 14.11M sh · $1.05B · Q2 2026
- Janus Henderson Group 13.18M sh · $978.61M · Q1 2026
- Farallon Capital Management 10.74M sh · $800.14M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 10.74M sh · $800.14M · Q2 2026
- Viking Global Investors 9.95M sh · $741.02M · Q2 2026
- VIKING GLOBAL INVESTORS LP 9.95M sh · $741.02M · Q2 2026
- Aisling Capital Management LP 3.09M sh · $203.30M · Q3 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 69.87M sh · $124.49M · Q2 2026
- SC US (TTGP), LTD. 1.86M sh · $122.41M · Q3 2026
- Frazier Life Sciences Management, L.P. 1.55M sh · $115.31M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.37M sh · $102.27M · Q2 2026
- Hood River Capital Management LLC 1.35M sh · $100.36M · Q2 2026
More on Prosight Management, LP
FAQ
How long has Prosight Management, LP held BBIO?
Prosight Management, LP has disclosed BBIO holdings in 9 of the last 11 reported quarters, going back to Q1 2024.
What is Prosight Management, LP's current position in BBIO?
As of Q3 2026, Prosight Management, LP holds 150.00K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $9.87M, representing 1.91% of its reported portfolio and ranking #18.
Has Prosight Management, LP been buying or selling BBIO?
In the latest 13F filing (Q3 2026), Prosight Management, LP newly opened its position in BBIO. The position peaked in Q3 2024 at 1.09M shares.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.